MASCC risk index for febrile neutropenia (also searched as the Multinational Association of Supportive Care in Cancer score, ICD-10: D70.9) is an internationally validated clinical prediction rule designed to quantify the probability of serious medical complications in adult cancer patients presenting with chemotherapy-induced febrile neutropenia1,4. Febrile neutropenia represents a life-threatening oncologic emergency characterized by fever and profound bone marrow suppression, historically mandating immediate hospital admission and broad-spectrum intravenous antimicrobial therapy for every patient. However, clinical recognition that a distinct subset of patients maintains a favorable prognosis enabled the development of the MASCC risk index to safely triage individuals into low-risk categories suitable for outpatient oral therapy or early discharge, thereby reducing unnecessary hospitalizations and healthcare costs without compromising patient safety2,3,4.

Etiology & Risk Factors

  • Cytotoxic Chemotherapy: The primary iatrogenic trigger, particularly regimens associated with high myelosuppression rates such as dose-dense breast cancer protocols, acute leukemia induction, and solid tumor palliative therapies3,4.
  • Patient-Related Vulnerabilities: Advanced age (over 65 years), baseline malnutrition, poor performance status (ECOG ≥2), active tobacco use, and underlying chronic comorbidities including renal insufficiency, hepatic dysfunction, and chronic obstructive pulmonary disease3.
  • Disease-Specific Factors: Hematologic malignancies (leukemias, high-grade lymphomas) versus solid tumors, extensive bone marrow infiltration by malignant cells, and recent radiation therapy involving major marrow-producing sites (pelvis, spine, sternum)2,3.
  • Microbiological Etiologies: Endogenous mucosal flora translocating across damaged gastrointestinal or respiratory tracts, predominantly Gram-negative bacilli (Pseudomonas aeruginosa, Escherichia coli, Klebsiella species) and Gram-positive cocci (Coagulase-negative staphylococci, Staphylococcus aureus, Streptococcus species)3.

Pathophysiology

Cytotoxic chemotherapy agents induce apoptosis and mitotic arrest in rapidly dividing hematopoietic progenitor cells within the bone marrow, precipitating a precipitous drop in circulating neutrophils (absolute neutrophil count [ANC] <0.5 × 10^9/L or expected drop below 0.4 × 10^9/L within 48 hours). Concurrently, chemotherapy causes direct mucosal barrier injury along the gastrointestinal tract, disrupting tight junctions and normal epithelial architecture. In the absence of an adequate neutrophil barrier, resident commensal bacteria and fungi readily translocate across the compromised mucosal interface into the systemic circulation. Without neutrophils to orchestrate a localized inflammatory containment response, invading pathogens rapidly proliferate, triggering systemic cytokine release (tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6) that manifests clinically as fever. The MASCC risk index mathematically integrates clinical burden of illness, hemodynamic parameters, and secondary organ dysfunctions to estimate the likelihood that this systemic inflammatory cascade will escalate into severe sepsis, septic shock, or multi-organ failure1,2,3,4.

MASCC risk index for febrile neutropenia — Pathophysiological Cascade & Clinical Flowchart 1 Cytotoxic Chemotherapy Myelosuppression causing profound neutropenia (<0.5 × 10^9/L) 2 Mucosal Barrier Breakdown Translocation of endogenous commensal flora into systemic circulation 3 Systemic Inflammatory Cascade Unopposed bacterial or fungal proliferation driving cytokine release and fever 4 Clinical Presentation Febrile neutropenia requiring immediate bedside risk stratification via MASCC score 5 Therapeutic Intervention Outpatient oral therapy for MASCC ≥21 versus inpatient IV antibiotics for MASCC <21

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Sudden onset of fever (single oral temperature ≥38.3°C or ≥38.0°C sustained over 1 hour) in a patient recently treated with myelosuppressive chemotherapy. Patients frequently report rigors, shaking chills, profound fatigue, generalized weakness, and subtle localized complaints such as odynophagia, dysuria, or mild cough that can rapidly evolve into catastrophic sepsis.
  • Physical Examination & Named Clinical Signs: Assessment must focus on vital sign stability to detect occult shock. Tachycardia, tachypnea, and hypotension indicate systemic inflammatory response syndrome (SIRS) or overt sepsis. Examination must meticulously inspect all potential portals of entry: oral mucosa for mucositis or candidiasis, perirectal area for fissures or abscesses (noting that digital rectal exams are strictly contraindicated due to mucosal seeding risks), central venous catheter exit sites for erythema and purulence, and skin integrity for cellulitis or ecthyma gangrenosum.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationMASCC Risk Index Calculation: Clinical scoring assessment executed immediately upon presentation to stratify risk score (≥21 = low risk; <21 = high risk)1,4.
Laboratory PanelComplete Blood Count (CBC) with differential demonstrating absolute neutrophil count <0.5 × 10^9/L; comprehensive metabolic panel revealing elevated serum creatinine, blood urea nitrogen, and transaminases indicative of end-organ hypoperfusion; baseline serum lactate (>2.0 mmol/L suggests tissue hypoperfusion).
Imaging / Radiology (X-ray, US, CT, MRI)Chest X-ray (CXR) mandatory to evaluate for pulmonary infiltrates or consolidation; computed tomography (CT) of the chest, abdomen, or sinuses if localized symptoms persist despite negative initial radiographs.
ECG / Histopathology / Procedural12-lead ECG to evaluate baseline cardiac rhythm and ischemia in patients presenting with tachycardia or hemodynamic instability; dual sets of blood cultures (one set from peripheral venipuncture and one set from each lumen of any central venous catheter) prior to antibiotic initiation.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Burden of Illness: No or mild symptomsAllocates 5 points. Patient maintains stable clinical status with minimal distress related to febrile neutropenia.
No Hypotension (Systolic BP >90 mmHg)Allocates 5 points. Preserved systemic vascular tone; absence of septic shock.
No Chronic Obstructive Pulmonary DiseaseAllocates 4 points. Absence of baseline chronic pulmonary disease that would otherwise impair physiological reserve.
Solid tumor or hematologic malignancy with no previous fungal infectionAllocates 4 points. Reflects lower baseline risk compared to active invasive mycoses.
No Dehydration requiring parenteral fluid therapyAllocates 3 points. Confirms intact oral intake and adequate intravascular volume status.
Burden of Illness: Moderate symptomsAllocates 3 points. Patient exhibits moderate clinical distress, requiring closer observation and supportive care.
Outpatient status at onset of feverAllocates 3 points. Patients presenting from the community generally experience lower rates of resistant hospital-acquired pathogens.
Age < 60 yearsAllocates 2 points. Younger physiological age correlates with enhanced organ reserve and superior outcomes.
Total Score InterpretationA cumulative score ≥21 defines low risk (approximate risk of severe complication <10%, suitable for outpatient oral therapy). A score <21 defines high risk (mandating mandatory inpatient admission and IV broad-spectrum antibiotics)1,2,4.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Non-Infectious Drug FeverFever temporally linked to recent administration of specific chemotherapeutic agents (e.g., bleomycin, cytarabine) or biological response modifiers; lacks systemic leukocytosis or positive blood cultures, and typically resolves promptly upon discontinuation or corticosteroid administration.
Tumor FeverDirect pyrogen release from rapidly proliferating malignant tissue (common in lymphomas and advanced solid tumors); fever patterns are often Pel-Ebstein or unremitting, unaccompanied by neutropenia-related mucosal breakdown, and responsive to naproxen or indomethacin trial.
Transfusion-Related ReactionAcute febrile non-hemolytic transfusion reaction occurring during or shortly after blood product administration; differentiated by direct temporal association with transfusion and absence of profound neutropenia or localized infectious foci.
Thromboembolic Disease (DVT / PE)Cancer-associated hypercoagulability precipitating deep vein thrombosis or pulmonary embolism; presents with localized extremity swelling or pleuritic chest pain and dyspnea, confirmed via Doppler ultrasound or CT pulmonary angiography.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Immediate evaluation of airway, breathing, and circulation. Secure large-bore peripheral intravenous access, initiate aggressive IV crystalloid resuscitation (e.g., 30 mL/kg balanced salt solution) if signs of tissue hypoperfusion or hypotension appear, and obtain immediate blood cultures before antimicrobial administration.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing):
    • High-Risk Patients (MASCC <21 or clinically unstable): Immediate inpatient hospitalization and empiric IV monotherapy with antipseudomonal beta-lactams such as Cefepime 2 g IV every 8 hours, Piperacillin-tazobactam 4.5 g IV every 6 hours, or Meropenem 1 g IV every 8 hours. In penicillin-allergic patients, administer Ciprofloxacin 400 mg IV every 12 hours combined with Vancomycin 15–20 mg/kg IV every 12 hours (adjusted for renal function).
    • Low-Risk Patients (MASCC ≥21 and stable): Outpatient combination oral therapy with Ciprofloxacin 500–750 mg PO twice daily plus Amoxicillin-clavulanate 875/125 mg PO twice daily (or Clindamycin 300–450 mg PO four times daily if penicillin-allergic). Patients must be observed in a clinical setting for at least 4–24 hours to confirm hemodynamic stability before definitive outpatient discharge2,4.
    • Adjunctive Growth Factor Support: Prophylactic or therapeutic Granulocyte Colony-Stimulating Factors (G-CSFs such as Filgrastim 5 mcg/kg/day subcutaneously or single-dose Pegfilgrastim 6 mg subcutaneously) may be considered to accelerate neutrophil recovery in selected high-risk cohorts5.
  • Surgical / Interventional Indications: Urgent surgical consultation and intervention for localized sources requiring drainage or debridement, including perirectal abscesses, necrotizing soft tissue infections, line-associated septic thrombophlebitis mandating central venous catheter removal, or obstructive typhlitis requiring bowel rest and surgical evaluation.

Complications & Prognosis

  • Key Acute Complications: Septic shock, multi-organ dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), acute kidney injury requiring renal replacement therapy, disseminated intravascular coagulation (DIC), and invasive fungal infections (e.g., pulmonary aspergillosis, candidemia)1,3.
  • Mortality and Morbidity Data: Untreated febrile neutropenia associated with severe sepsis carries a mortality rate exceeding 40% within the first 48 hours. Conversely, timely risk stratification via the MASCC index combined with prompt antimicrobial administration successfully reduces overall mortality to less than 5% in low-risk outpatient cohorts2,3.
  • Prognostic Factors: Favorable prognosis correlates with higher initial MASCC scores (≥21), rapid neutrophil recovery (>0.5 × 10^9/L within 7 days), absence of documented bacteremia, solid tumor etiology versus refractory acute leukemia, and preserved baseline functional status1,3.